



Endure Biotherapeutics Announces Acceptance to the California Life Sciences FAST Program

San Diego, Calif., October 4, 2023 – Endure Biotherapeutics, a private biotechnology company developing engineered, engraftable, live biotherapeutics for metabolic diseases, today announced the company’s acceptance into the California Life Sciences (CLS) FAST advisory program as a part of its 2023 Fall Cohort.

“We are excited to be a part of the FAST Fall 2023 Cohort and look forward to leveraging their advisory and strategic capabilities as we advance our next generation engineered native bacteria platform technology,” said Mark S. Wilson, CEO of Endure Biotherapeutics. “California Life Sciences has consistently shown the ability to support early-stage companies like ours with cutting-edge technology and the potential to transform the current treatment paradigm of diseases with significant unmet need. We look forward to this exciting new chapter as Endure continues to grow.”

FAST California provides early-stage founders of disruptive innovative life science technology companies with a customized advisory program to perfect their business models, assess strategic focus, maximize IP and help develop a milestone and scale-up plan to exit. A group of curated advisors, each with deep domain expertise, will work with them over twelve weeks to build a compelling commercialization strategy and prepare them for an Innovation Showcase to a curated audience of potential investors and collaboration partners.

About Endure Biotherapeutics:

Endure Biotherapeutics (Endure Bio) is developing engineered, engraftable, live biotherapeutics for metabolic diseases by genetically engineering native human bacteria to express therapeutic compounds. The company’s platform overcomes the traditional challenges of first-generation products, allowing for engraftable knock-in function with infrequent administration, delivering potentially curative solutions that remain resident and endure the host environment. The company is focused on addressing phenylketonuria (PKU) and other orphan disease applications.

For Investors:

Stephen Jasper

Gilmartin Group

stephen@gilmartinir.com